OPT Projected Dividend Yield
ADR (Sponsored) (New)/Opthea Ltd ( NASDAQ : OPT )Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. Co. is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. 21 YEAR PERFORMANCE RESULTS |
OPT Dividend History Detail OPT Dividend News OPT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |